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Haematology/oncology and trauma and 
orthopaedics do marry. The well thought out article 
by the group led by Prof. Selleri [1] elegantly points 
up what, empirically, some of us already knew: 
haematopoietic stem cell transplantation does save 
lives and prolongs survival, but the price to pay, for 
the musculoskeletal system, can be high. Bone is a 
composite tissue, of which its haematopoietic 
component is a major part. The societal impact of 
autologous and allogeneic haematopoietic stem cell 
transplantation for the management of malignant and 
non-malignant haematological conditions has now 
become common place, and Salerno is a leading 
centre in the Mediterrean and Europe in this field. 
Nevertheless, there is a price to pay: it is possible 
that, by depriving bone of ‘its own’ haematopoietic 
bone marrow, the result is that the local metabolism 
is altered. This, coupled with the vast array of drugs 
that these patients receive, may well result in the 
deleterious effects on the musculoskeletal system 
that are described in this article. The association 
between corticosteroids and avascular necrosis of the 
femoral head is well described, but, if it is associated 
with osteoporosis, the resulting combination could 
well be very difficult to manage: any reconstructive 
procedures may be destined to fail.  
In addition, although not reported in this 
investigation, it is likely that the levels of activities 
of such patients may well drop following these 
taxing treatments, and that the cocktail of drugs and 
the transplant themselves may have noxious effect 
on muscles, with sarcopenia: the effects on bone 
tissue are disastrous.  
Monitoring bone mineral density  using 
ultrasonography or DEXA is feasible, but the costs 
of such programmes should be put in the context of 
never ending cuts to the National Health Service. 
One should ask whether they satisfy the central 
tenets of screening: even though we can identify the 
amount of bone loss and we can prospectively 
monitor it, is it correctable, and will it make a 
clinically relevant difference? The authors rightly 
point out that bisphosponates (the use of which is 
already frowned upon in some orthopaedic and 
rheumatological circles) are badly tolerated in 
recipients of haematopoietic stem cell 
transplantation. It may be that, contrary to what big 
pharma wants us to believe, the best approach is to 
introduce controlled regular physical exercises [2]: 
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